Nemvaleukin alfa is a fusion protein commercialized by Alkermes, with a leading Phase III program in Fallopian Tube Cancer, Peritoneal Cancer and Epithelial Ovarian Cancer. According to Globaldata, it is involved in 6 clinical trials, of which 1 was completed, and 5 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Nemvaleukin alfa’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Nemvaleukin alfa is expected to reach an annual total of $64 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Nemvaleukin alfa Overview
Nemvaleukin alfa (ALKS-4230) is under development for the treatment of advanced solid tumors in both refractory and treatment naive patients, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), extrahepatic bile duct cancer, cervical cancer, endometrial cancer, adenocarcinoma of the gastroesophageal junction, esophageal cancer, recurrent head and neck squamous cell carcinoma, gastric cancer, melanoma, renal cell carcinoma, urothelial carcinoma and microsatellite instability-high cancers including colorectal cancer, triple-negative breast cancer, ovarian carcinoma, chondrosarcoma, pancreatic cancer, rectal cancer, soft tissue sarcomas, lymphoma and patients with metastatic NSCLC whose tumors express low or undetectable PD-L1. The drug candidate is administered as intravenous infusion and subcutaneous route. It is a new biologic entity based on fusion of IL-2 and its receptors (IL-2 receptor alpha). The transactivation and coordinate expression of IL-2 and IL-2R alpha enhances tumor killing T cells. It is developed using Picasso platform which is a fusion protein technology platform that modulates the natural mechanism of action of a biologic and provides safety and tolerability advantages.
Alkermes is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company’s proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants licenses under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. The company has global operations. Alkermes is headquartered in Dublin, Ireland.
The company reported revenues of (US Dollars) US$1,111.8 million for the fiscal year ended December 2022 (FY2022), a decrease of 5.3% over FY2021. The operating loss of the company was US$142.3 million in FY2022, compared to an operating loss of US$32.3 million in FY2021. The net loss of the company was US$158.3 million in FY2022, compared to a net loss of US$48.2 million in FY2021.
For a complete picture of Nemvaleukin alfa’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.